avapritinib
blueprint medicines,illumina
['pathfinder']
dr. deborah schrag presents #aacr23 about the progress and limitations of mced tests, pathfinder, nhs, and future trials already under way including vanguard and strategies to accelerate translation. 
Physician-Scientist; Med-Onc; Pubs https://t.co/8RMRruPhfx Director @BrownUCancer Assoc Dean @BrownMedicine @americancancer Professor; Inventor, Entrepreneur